Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
RESEARCH TOOLSreports
Holding EWTX?
Track your performance easily
EWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.93 - $38.12
Previous Close$31.95
Volume172.07K
Average Volume (3M)1.14M
Market Cap
$3.00B
Enterprise Value$2.50B
Total Cash (Recent Filing)$492.54M
Total Debt (Recent Filing)$4.44M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Feb 20, 2025EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding94,688,517
10 Day Avg. Volume708,058
30 Day Avg. Volume1,142,221
Standard Deviation0.22
R-Squared0.00108
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.19
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-19.36
Forecast
1Y Price Target
$42.00Price Target Upside30.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Edgewise Therapeutics News
PremiumCompany Announcements
Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And Market PositionEDG-7500 demonstrates a 67% mean reduction in resting LVOT gradient in patients with obstructive hypertrophic cardiomyopathy, clearly differentiating it from existing cardiac myosin inhibitors.
Regulatory Approval PotentialEWTX anticipates a discussion with the FDA for potential accelerated approval of its treatment for Becker muscular dystrophy if the Phase 2 CANYON study results are successful.
Safety And TolerabilityEDG-7500 is well tolerated across a wide range of doses in healthy volunteers, showing no significant changes in left ventricular ejection fraction, which suggests a favorable safety profile.
Bears Say
Market ReactionAfter EWTX participated in a competitor's event, the stock experienced a significant drop of about 17% due to market speculation.
Project DelaysEWTX has delayed their DMD readout to the fourth quarter of 2024, causing investors to focus on other projects.
Study ChallengesIf EWTX fails to meet the target in the CANYON study, the company will need to revise the study design.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $5.93 and its highest was $38.12 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Currently, no data Available
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 91 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.372 by $0.012.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -$0.4.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 94,688,515 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.372. Following the earnings report the stock price went down -3.25%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Among the largest hedge funds holding Edgewise Therapeutics’s share is RA Capital Management. It holds Edgewise Therapeutics’s shares valued at 238M.
---
Edgewise Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (30.56% Upside)
$42.00 (30.56% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 235.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
396.88%
12-Months-Change
Fundamentals
Return on Equity
-31.90%
Trailing 12-Months
Asset Growth
64.21%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
---
EWTX Stock 12 Month Forecast
Average Price Target
$42.00
▲(30.56% Upside)
Technical Analysis
Best Analysts Covering EWTX
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+80.31%
assigned a buy rating 15 days ago
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +80.31% per trade.
---